Mirai Bio

Mirai Bio is a life-sciences company or investment vehicle whose name evokes the Japanese word for future and a biology-forward orientation. The disclosed footprint is limited and the entity could be either an operating biotech company with venture-style activity, a small biotech-focused fund, or a corporate vehicle, which founders should clarify before approaching. Assuming venture-investing activity, healthcare exposure is total and biology-focused, with plausible interest in therapeutics tools, computational biology, drug discovery platforms, and biomanufacturing. AI focus is plausibly central given the broader trend in AI-for-biology investing, with interest in models trained on biological data rather than horizontal AI. Without disclosed stage or check data, founders should anchor expectations to a small specialist vehicle: pre-seed and seed checks plausibly in the USD 250K to USD 1M range, often co-investing alongside larger biotech leads. This is the wrong door for digital health, healthcare services, or any non-biology software business. It is a possible fit for early biology-focused teams looking for a thesis-aligned co-investor with possible Japan or Asia-Pacific connectivity. Entry path is the website and any disclosed LinkedIn presence; warm introductions from biotech operators and academic founders are by far the most reliable approach given the limited public footprint. Founders should clarify the entity type early and arrive with rigorous scientific data; biology investors at this scale do not fund narrative pitches.